Brokerages Set BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Target Price at $14.67

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) has been given a consensus rating of “Buy” by the five research firms that are presently covering the company, Marketbeat reports. Five investment analysts have rated the stock with a buy recommendation. The average twelve-month price target among analysts that have issued ratings on the stock in the last year is $15.40.

Several equities analysts have recently weighed in on BCRX shares. HC Wainwright reissued a “buy” rating and set a $30.00 target price on shares of BioCryst Pharmaceuticals in a research report on Tuesday, May 7th. JMP Securities raised their target price on shares of BioCryst Pharmaceuticals from $14.00 to $15.00 and gave the stock a “market outperform” rating in a report on Tuesday, May 7th. Finally, Needham & Company LLC reiterated a “buy” rating and set a $12.00 price target on shares of BioCryst Pharmaceuticals in a report on Tuesday, May 7th.

BioCryst Pharmaceuticals Stock Performance

BCRX stock opened at $7.51 on Thursday. The firm has a fifty day moving average price of $6.69 and a 200 day moving average price of $5.77. BioCryst Pharmaceuticals has a fifty-two week low of $4.03 and a fifty-two week high of $7.93. The firm has a market cap of $1.55 billion, a PE ratio of -7.02 and a beta of 1.88.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last announced its earnings results on Monday, August 5th. The biotechnology company reported ($0.06) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.17) by $0.11. The business had revenue of $109.30 million for the quarter, compared to analysts’ expectations of $98.30 million. The firm’s quarterly revenue was up 34.9% compared to the same quarter last year. During the same quarter in the prior year, the company posted ($0.24) earnings per share. On average, equities analysts predict that BioCryst Pharmaceuticals will post -0.65 EPS for the current year.

Insider Buying and Selling

In other BioCryst Pharmaceuticals news, Director Amy E. Mckee sold 8,600 shares of the company’s stock in a transaction dated Monday, June 24th. The shares were sold at an average price of $6.32, for a total value of $54,352.00. Following the transaction, the director now directly owns 27,831 shares in the company, valued at approximately $175,891.92. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. In other news, Director Amy E. Mckee sold 8,600 shares of the stock in a transaction on Monday, June 24th. The stock was sold at an average price of $6.32, for a total transaction of $54,352.00. Following the transaction, the director now owns 27,831 shares of the company’s stock, valued at approximately $175,891.92. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, Director Steven K. Galson purchased 21,940 shares of the business’s stock in a transaction dated Monday, May 13th. The shares were purchased at an average price of $5.49 per share, for a total transaction of $120,450.60. Following the purchase, the director now owns 51,551 shares of the company’s stock, valued at approximately $283,014.99. The disclosure for this purchase can be found here. Insiders have purchased 103,601 shares of company stock valued at $596,338 in the last 90 days. Company insiders own 4.80% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in BCRX. Vanguard Group Inc. lifted its position in shares of BioCryst Pharmaceuticals by 15.4% during the fourth quarter. Vanguard Group Inc. now owns 17,763,720 shares of the biotechnology company’s stock valued at $106,405,000 after buying an additional 2,371,401 shares during the last quarter. Avoro Capital Advisors LLC raised its stake in shares of BioCryst Pharmaceuticals by 13.0% during the 4th quarter. Avoro Capital Advisors LLC now owns 13,050,000 shares of the biotechnology company’s stock worth $78,170,000 after acquiring an additional 1,500,000 shares in the last quarter. Kynam Capital Management LP boosted its stake in BioCryst Pharmaceuticals by 41.9% in the first quarter. Kynam Capital Management LP now owns 6,527,491 shares of the biotechnology company’s stock valued at $33,160,000 after acquiring an additional 1,927,491 shares in the last quarter. Braidwell LP boosted its stake in BioCryst Pharmaceuticals by 6.6% in the fourth quarter. Braidwell LP now owns 5,718,477 shares of the biotechnology company’s stock valued at $34,254,000 after acquiring an additional 355,497 shares in the last quarter. Finally, Norges Bank purchased a new position in BioCryst Pharmaceuticals in the fourth quarter worth $13,278,000. 85.88% of the stock is currently owned by hedge funds and other institutional investors.

BioCryst Pharmaceuticals Company Profile

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.